Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Crysvita (burosumab-twza) for Treating X–Linked Hypophosphatemia

Crysvita® (burosumab-twza) is a FGF23 blocking antibody indicated for the treatment of XLH in adults and children. Image courtesy of Emw.



  • Cyrsvita®
  • Cyrsvita®
  • Cyrsvita®

Go Top